| Dr Eric Hong, MD | |
|
9834 Genesee Ave, Suite 300, La Jolla, CA 92037-1223 | |
| (858) 824-2900 | |
| (858) 824-2910 |
| Full Name | Dr Eric Hong |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 18 Years |
| Location | 9834 Genesee Ave, La Jolla, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013162452 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | A101767 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Scripps Memorial Hospital - Encinitas | Encinitas, CA | Hospital |
| Scripps Memorial Hospital La Jolla | La jolla, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency And Acute Care Medical Corporation | 9537108279 | 382 |
| San Diego Cardiovascular Associates Medical Group Inc | 0840270757 | 14 |
| Scripps Cardiology Medical Group, Inc. | 3971547951 | 19 |
News Archive
Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now Dental office in Fountain Valley – the 50th office in Southern California. Bright Now Dental will continue its growth pattern in Southern California over the next two years, with offices slated to open in Escondido, Simi Valley, El Cajon, and Upland later this year and further expansion in 2012.
University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.
Breast cancer survivors like many other cancer survivors live in fear of relapse of their cancer after they have been in remission. Researchers have now developed a tool by which they can predict accurately the time when the cancer is likely to return. The results of this study were published in the latest issue of the journal Nature.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
› Verified 1 days ago
| Entity Name | San Diego Cardiovascular Associates Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427069103 PECOS PAC ID: 0840270757 Enrollment ID: O20040721001638 |
News Archive
Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now Dental office in Fountain Valley – the 50th office in Southern California. Bright Now Dental will continue its growth pattern in Southern California over the next two years, with offices slated to open in Escondido, Simi Valley, El Cajon, and Upland later this year and further expansion in 2012.
University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.
Breast cancer survivors like many other cancer survivors live in fear of relapse of their cancer after they have been in remission. Researchers have now developed a tool by which they can predict accurately the time when the cancer is likely to return. The results of this study were published in the latest issue of the journal Nature.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
› Verified 1 days ago
| Entity Name | Emergency And Acute Care Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437103942 PECOS PAC ID: 9537108279 Enrollment ID: O20050502000734 |
News Archive
Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now Dental office in Fountain Valley – the 50th office in Southern California. Bright Now Dental will continue its growth pattern in Southern California over the next two years, with offices slated to open in Escondido, Simi Valley, El Cajon, and Upland later this year and further expansion in 2012.
University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.
Breast cancer survivors like many other cancer survivors live in fear of relapse of their cancer after they have been in remission. Researchers have now developed a tool by which they can predict accurately the time when the cancer is likely to return. The results of this study were published in the latest issue of the journal Nature.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
› Verified 1 days ago
| Entity Name | Scripps Cardiology Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851481121 PECOS PAC ID: 3971547951 Enrollment ID: O20050610000908 |
News Archive
Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now Dental office in Fountain Valley – the 50th office in Southern California. Bright Now Dental will continue its growth pattern in Southern California over the next two years, with offices slated to open in Escondido, Simi Valley, El Cajon, and Upland later this year and further expansion in 2012.
University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.
Breast cancer survivors like many other cancer survivors live in fear of relapse of their cancer after they have been in remission. Researchers have now developed a tool by which they can predict accurately the time when the cancer is likely to return. The results of this study were published in the latest issue of the journal Nature.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
› Verified 1 days ago
| Entity Name | San Diego Cardiovascular Associates Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Intensive Cardiac Rehabilitation |
| Entity Identifiers | NPI Number: 1427069103 PECOS PAC ID: 0840270757 Enrollment ID: O20231208000504 |
News Archive
Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now Dental office in Fountain Valley – the 50th office in Southern California. Bright Now Dental will continue its growth pattern in Southern California over the next two years, with offices slated to open in Escondido, Simi Valley, El Cajon, and Upland later this year and further expansion in 2012.
University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.
Breast cancer survivors like many other cancer survivors live in fear of relapse of their cancer after they have been in remission. Researchers have now developed a tool by which they can predict accurately the time when the cancer is likely to return. The results of this study were published in the latest issue of the journal Nature.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Hong, MD 320 Santa Fe Dr, Suite 204, Encinitas, CA 92024-5138 Ph: (858) 824-2900 | Dr Eric Hong, MD 9834 Genesee Ave, Suite 300, La Jolla, CA 92037-1223 Ph: (858) 824-2900 |
News Archive
Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now Dental office in Fountain Valley – the 50th office in Southern California. Bright Now Dental will continue its growth pattern in Southern California over the next two years, with offices slated to open in Escondido, Simi Valley, El Cajon, and Upland later this year and further expansion in 2012.
University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.
Breast cancer survivors like many other cancer survivors live in fear of relapse of their cancer after they have been in remission. Researchers have now developed a tool by which they can predict accurately the time when the cancer is likely to return. The results of this study were published in the latest issue of the journal Nature.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
› Verified 1 days ago
Dr. John Sturdivant Andrews, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1223 Via Barranca, La Jolla, CA 92037 Phone: 858-775-1976 | |
Dr. Mark C Adrian, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9850 Genesee Ave, Suite 355, La Jolla, CA 92037 Phone: 858-202-0011 | |
Dr. Erminia M. Guarneri, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-3330 Fax: 858-784-5933 | |
Katrina Deleon, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-6158 | |
Abhishek Gadre, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9300 Campus Point Dr, La Jolla, CA 92037 Phone: 858-657-7118 | |
Kamran Hussain Imam, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-6158 |